![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CDYL |
Gene summary for CDYL |
![]() |
Gene information | Species | Human | Gene symbol | CDYL | Gene ID | 9425 |
Gene name | chromodomain Y like | |
Gene Alias | CDYL1 | |
Cytomap | 6p25.1 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9Y232 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9425 | CDYL | SYSMH1 | Human | Oral cavity | OSCC | 1.11e-14 | 4.31e-01 | 0.1127 |
9425 | CDYL | SYSMH2 | Human | Oral cavity | OSCC | 2.85e-09 | 3.48e-01 | 0.2326 |
9425 | CDYL | SYSMH3 | Human | Oral cavity | OSCC | 1.40e-22 | 7.01e-01 | 0.2442 |
9425 | CDYL | SYSMH5 | Human | Oral cavity | OSCC | 4.13e-15 | 4.21e-01 | 0.0647 |
9425 | CDYL | male-WTA | Human | Thyroid | PTC | 5.63e-10 | 1.52e-01 | 0.1037 |
9425 | CDYL | PTC01 | Human | Thyroid | PTC | 7.83e-10 | 2.27e-01 | 0.1899 |
9425 | CDYL | PTC04 | Human | Thyroid | PTC | 1.02e-14 | 2.39e-01 | 0.1927 |
9425 | CDYL | PTC05 | Human | Thyroid | PTC | 3.66e-18 | 6.50e-01 | 0.2065 |
9425 | CDYL | PTC06 | Human | Thyroid | PTC | 3.82e-30 | 7.02e-01 | 0.2057 |
9425 | CDYL | PTC07 | Human | Thyroid | PTC | 2.84e-36 | 6.39e-01 | 0.2044 |
9425 | CDYL | ATC09 | Human | Thyroid | ATC | 8.22e-07 | 2.81e-01 | 0.2871 |
9425 | CDYL | ATC11 | Human | Thyroid | ATC | 7.57e-03 | 2.55e-01 | 0.3386 |
9425 | CDYL | ATC12 | Human | Thyroid | ATC | 7.05e-19 | 4.34e-01 | 0.34 |
9425 | CDYL | ATC13 | Human | Thyroid | ATC | 1.63e-41 | 7.82e-01 | 0.34 |
9425 | CDYL | ATC1 | Human | Thyroid | ATC | 9.26e-08 | 3.72e-01 | 0.2878 |
9425 | CDYL | ATC2 | Human | Thyroid | ATC | 4.08e-08 | 9.14e-01 | 0.34 |
9425 | CDYL | ATC3 | Human | Thyroid | ATC | 1.05e-02 | 2.03e-01 | 0.338 |
9425 | CDYL | ATC4 | Human | Thyroid | ATC | 2.64e-23 | 5.45e-01 | 0.34 |
9425 | CDYL | ATC5 | Human | Thyroid | ATC | 1.48e-44 | 8.41e-01 | 0.34 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
GO:00400295 | Esophagus | ESCC | regulation of gene expression, epigenetic | 74/8552 | 105/18723 | 2.24e-07 | 3.42e-06 | 74 |
GO:00090484 | Esophagus | ESCC | dosage compensation by inactivation of X chromosome | 14/8552 | 16/18723 | 6.78e-04 | 3.56e-03 | 14 |
GO:00075494 | Esophagus | ESCC | dosage compensation | 14/8552 | 18/18723 | 5.77e-03 | 2.14e-02 | 14 |
GO:0043543 | Liver | NAFLD | protein acylation | 43/1882 | 243/18723 | 1.70e-04 | 3.07e-03 | 43 |
GO:00435432 | Liver | HCC | protein acylation | 157/7958 | 243/18723 | 2.40e-12 | 1.12e-10 | 157 |
GO:0040029 | Liver | HCC | regulation of gene expression, epigenetic | 61/7958 | 105/18723 | 9.02e-04 | 5.31e-03 | 61 |
GO:0009048 | Liver | HCC | dosage compensation by inactivation of X chromosome | 13/7958 | 16/18723 | 1.84e-03 | 9.42e-03 | 13 |
GO:0007549 | Liver | HCC | dosage compensation | 13/7958 | 18/18723 | 1.05e-02 | 3.89e-02 | 13 |
GO:00435434 | Oral cavity | OSCC | protein acylation | 149/7305 | 243/18723 | 1.33e-12 | 5.80e-11 | 149 |
GO:00400294 | Oral cavity | OSCC | regulation of gene expression, epigenetic | 59/7305 | 105/18723 | 2.62e-04 | 1.68e-03 | 59 |
GO:00090483 | Oral cavity | OSCC | dosage compensation by inactivation of X chromosome | 13/7305 | 16/18723 | 7.05e-04 | 3.89e-03 | 13 |
GO:00075493 | Oral cavity | OSCC | dosage compensation | 13/7305 | 18/18723 | 4.45e-03 | 1.79e-02 | 13 |
GO:004354321 | Oral cavity | EOLP | protein acylation | 51/2218 | 243/18723 | 3.11e-05 | 4.41e-04 | 51 |
GO:00400292 | Oral cavity | EOLP | regulation of gene expression, epigenetic | 24/2218 | 105/18723 | 1.07e-03 | 7.87e-03 | 24 |
GO:00090481 | Oral cavity | EOLP | dosage compensation by inactivation of X chromosome | 7/2218 | 16/18723 | 1.40e-03 | 9.58e-03 | 7 |
GO:00075491 | Oral cavity | EOLP | dosage compensation | 7/2218 | 18/18723 | 3.15e-03 | 1.84e-02 | 7 |
GO:00400293 | Oral cavity | NEOLP | regulation of gene expression, epigenetic | 24/2005 | 105/18723 | 2.48e-04 | 2.55e-03 | 24 |
GO:004354331 | Oral cavity | NEOLP | protein acylation | 40/2005 | 243/18723 | 3.85e-03 | 2.21e-02 | 40 |
GO:00090482 | Oral cavity | NEOLP | dosage compensation by inactivation of X chromosome | 6/2005 | 16/18723 | 4.64e-03 | 2.56e-02 | 6 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CDYL | SNV | Missense_Mutation | novel | c.1542G>T | p.Glu514Asp | p.E514D | Q9Y232 | protein_coding | deleterious(0.03) | benign(0.017) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
CDYL | SNV | Missense_Mutation | novel | c.1285G>A | p.Asp429Asn | p.D429N | Q9Y232 | protein_coding | tolerated(0.14) | possibly_damaging(0.879) | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
CDYL | SNV | Missense_Mutation | c.524N>G | p.Asp175Gly | p.D175G | Q9Y232 | protein_coding | tolerated(0.5) | possibly_damaging(0.72) | TCGA-BH-A0DQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
CDYL | SNV | Missense_Mutation | novel | c.1204N>G | p.Ile402Val | p.I402V | Q9Y232 | protein_coding | tolerated(0.06) | benign(0.072) | TCGA-BH-A42T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CDYL | SNV | Missense_Mutation | c.923N>T | p.Ser308Leu | p.S308L | Q9Y232 | protein_coding | deleterious(0) | possibly_damaging(0.571) | TCGA-GM-A2DD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | CR | |
CDYL | deletion | Frame_Shift_Del | novel | c.675delN | p.Ala226LeufsTer14 | p.A226Lfs*14 | Q9Y232 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
CDYL | deletion | Frame_Shift_Del | novel | c.1354delN | p.Gly452AspfsTer4 | p.G452Dfs*4 | Q9Y232 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
CDYL | SNV | Missense_Mutation | rs370584550 | c.1463N>T | p.Ser488Leu | p.S488L | Q9Y232 | protein_coding | tolerated(0.12) | benign(0.047) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
CDYL | SNV | Missense_Mutation | c.149N>A | p.Ser50Asn | p.S50N | Q9Y232 | protein_coding | deleterious_low_confidence(0.03) | benign(0) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
CDYL | SNV | Missense_Mutation | c.999N>A | p.Ser333Arg | p.S333R | Q9Y232 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |